DBV Technologies S.A. approved its 2026 Performance Share Unit Plan and granted 4,060,000 performance share units (PSUs) to CEO Daniel Tassé. The award is contingent upon FDA approval of Viaskin Peanut biologics license applications, with 2,900,000 PSUs vesting upon the first approval and 1,160,000 PSUs vesting upon a second approval.
